Ideaya Biosciences is projected to report a Q2 2026 loss of $1.18 per share on revenue of $7.40 million, with the current stock price of $35.50 trading at a significant discount to the consensus analyst target of $53.54.
Investors are primarily focused on the progress of the Darovasertib New Drug Application (NDA) filing, which the company aims to complete in the second half of 2026 following positive registrational trial data in metastatic uveal melanoma.
The market is also closely monitoring clinical updates from the IDE397 and IDE892 programs and the status of a cash runway currently extending into 2030. Despite widening losses driven by intensified clinical trial activity, analyst sentiment remains a "Strong Buy" based on Ideaya's leadership in the precision oncology and synthetic lethality space.